Claes Dahlgren Selected Research

Formyl Peptide Receptors (Formyl Peptide Receptor)

1/2022	GRK2 selectively attenuates the neutrophil NADPH-oxidase response triggered by β-arrestin recruiting GPR84 agonists.
1/2019	Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
1/2016	Basic characteristics of the neutrophil receptors that recognize formylated peptides, a danger-associated molecular pattern generated by bacteria and mitochondria.
1/2016	The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
6/2013	Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
6/2012	Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species.
6/2009	International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.
12/2008	Tumour necrosis factor (TNF)-alpha primes murine neutrophils when triggered via formyl peptide receptor-related sequence 2, the murine orthologue of human formyl peptide receptor-like 1, through a process involving the type I TNF receptor and subcellular granule mobilization.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claes Dahlgren Research Topics

Disease

17	Inflammation (Inflammations) 01/2022 - 03/2009
9	Infections 04/2020 - 12/2004
3	Chronic Granulomatous Disease 01/2019 - 12/2010
2	Rheumatoid Arthritis 06/2010 - 02/2008
2	Necrosis 12/2008 - 06/2004
1	Acquired Immunodeficiency Syndrome (AIDS) 04/2020
1	Gingival Pocket 01/2020
1	Animal Disease Models 01/2019
1	Sepsis (Septicemia) 01/2015
1	Tuberculosis (Tuberculoses) 01/2015
1	Autolysis 09/2008
1	Guillain-Barre Syndrome 12/2007
1	Autoimmune Diseases (Autoimmune Disease) 12/2007
1	Wounds and Injuries (Trauma) 04/2007
1	Atherosclerosis 03/2005
1	Carcinogenesis 12/2004

Drug/Important Bio-Agent (IBA)

8	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2022 - 12/2008
7	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2020 - 12/2007
4	LigandsIBA 04/2020 - 01/2016
4	Chemotactic FactorsIBA 04/2020 - 01/2013
4	Peptides (Polypeptides)IBA 01/2019 - 12/2008
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 12/2004
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 05/2018 - 06/2009
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 05/2018
2	CytokinesIBA 01/2017 - 12/2008
2	EnzymesIBA 01/2017 - 09/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2016 - 12/2008
2	Antimicrobial Cationic PeptidesIBA 01/2015 - 03/2009
2	Serum Amyloid A Protein (Serum Amyloid A)IBA 06/2010 - 02/2008
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2010 - 02/2008
1	Pharmaceutical PreparationsIBA 01/2021
1	neutrophil cytosol factor 40KIBA 10/2019
1	IntegrinsIBA 01/2019
1	Mitochondrial DNA (mtDNA)IBA 01/2019
1	L-SelectinIBA 01/2019
1	Volatile Fatty AcidsIBA 10/2016
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2015
1	Biological ProductsIBA 01/2015
1	Proteins (Proteins, Gene)FDA Link 01/2015
1	Trp-Lys-Tyr-Met-Val-MetIBA 12/2008
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2008
1	Streptococcus pneumoniae plY proteinIBA 09/2008
1	Blood Proteins (Serum Proteins)IBA 02/2008
1	EndotoxinsIBA 04/2007
1	AcidsIBA 04/2007
1	AntioxidantsIBA 03/2005
1	oxidized low density lipoproteinIBA 03/2005
1	Antiviral Agents (Antivirals)IBA 12/2004
1	Platelet Activating FactorIBA 06/2004

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2015